Cns Historical Balance Sheet

CNSP Stock

USD 0.1 0 3.30%

Trend analysis of Cns Pharmaceuticals balance sheet accounts such as Short Long Term Debt Total of 362.4 K, Other Current Liabilities of 7 M or Total Current Liabilities of 7.4 M provides information on Cns Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Cns Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Cns Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Cns Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cns Pharmaceuticals is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Cns Stock, please use our How to Invest in Cns Pharmaceuticals guide.

About Cns Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Cns Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Cns Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Cns Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Cns currently owns. An asset can also be divided into two categories, current and non-current.

Cns Pharmaceuticals Balance Sheet Chart

At this time, Cns Pharmaceuticals' Total Liabilities is relatively stable compared to the past year. As of 02/01/2025, Short and Long Term Debt is likely to grow to about 362.4 K, while Net Tangible Assets are likely to drop slightly above 6 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Total Assets

Total assets refers to the total amount of Cns Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cns Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Cns Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cns Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Cns Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Cns Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Cns Stock, please use our How to Invest in Cns Pharmaceuticals guide.At this time, Cns Pharmaceuticals' Total Liabilities is relatively stable compared to the past year. As of 02/01/2025, Short and Long Term Debt is likely to grow to about 362.4 K, while Net Tangible Assets are likely to drop slightly above 6 M.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	410.0K	300.8K	345.9K	362.4K
Total Assets	13.1M	1.7M	2.0M	1.9M

Short Long Term Debt Total Total Assets

Cns Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Net Working Capital	Short Term Debt	Common Stock	Current Deferred Revenue	Other Assets
Total Assets		0.79	-0.08	0.22	0.87	0.83	-0.98	-0.34	0.15	0.99	0.99	0.67	0.16	0.77	0.62	0.74	0.42	0.22	0.88	0.79	1.0	0.86	0.79	0.44	-0.74	0.42
Short Long Term Debt Total	0.79		0.39	0.59	0.48	0.88	-0.72	-0.67	0.53	0.73	0.73	0.83	-0.4	0.5	0.87	0.68	0.74	0.59	0.5	1.0	0.78	0.46	1.0	0.28	-0.91	0.34
Other Current Liab	-0.08	0.39		0.92	-0.54	0.42	0.18	-0.86	0.95	-0.16	-0.16	0.58	-0.66	-0.2	0.7	0.23	0.84	0.92	-0.52	0.39	-0.08	-0.55	0.39	-0.42	-0.53	-0.28
Total Current Liabilities	0.22	0.59	0.92		-0.28	0.58	-0.1	-0.97	0.99	0.12	0.12	0.77	-0.45	0.19	0.86	0.58	0.97	1.0	-0.26	0.59	0.21	-0.31	0.59	-0.39	-0.71	-0.16
Total Stockholder Equity	0.87	0.48	-0.54	-0.28		0.52	-0.92	0.15	-0.35	0.91	0.91	0.27	0.38	0.66	0.18	0.43	-0.07	-0.28	1.0	0.48	0.87	1.0	0.48	0.63	-0.37	0.49
Net Tangible Assets	0.83	0.88	0.42	0.58	0.52		-0.78	-0.67	0.55	0.79	0.79	0.88	-0.3	0.4	0.88	0.61	0.74	0.58	0.54	0.88	0.83	0.51	0.88	0.32	-0.93	0.3
Net Debt	-0.98	-0.72	0.18	-0.1	-0.92	-0.78		0.21	-0.02	-1.0	-1.0	-0.56	-0.17	-0.7	-0.51	-0.63	-0.3	-0.1	-0.92	-0.72	-0.99	-0.91	-0.72	-0.44	0.65	-0.33
Retained Earnings	-0.34	-0.67	-0.86	-0.97	0.15	-0.67	0.21		-0.96	-0.23	-0.23	-0.86	0.41	-0.28	-0.92	-0.66	-0.98	-0.97	0.13	-0.67	-0.33	0.18	-0.67	0.26	0.82	0.0
Accounts Payable	0.15	0.53	0.95	0.99	-0.35	0.55	-0.02	-0.96		0.05	0.05	0.73	-0.47	0.1	0.84	0.52	0.96	0.99	-0.33	0.53	0.14	-0.38	0.53	-0.39	-0.69	-0.15
Cash	0.99	0.73	-0.16	0.12	0.91	0.79	-1.0	-0.23	0.05		1.0	0.58	0.16	0.71	0.53	0.64	0.32	0.12	0.91	0.73	0.99	0.9	0.73	0.43	-0.66	0.34
Cash And Short Term Investments	0.99	0.73	-0.16	0.12	0.91	0.79	-1.0	-0.23	0.05	1.0		0.58	0.16	0.71	0.53	0.64	0.32	0.12	0.91	0.73	0.99	0.9	0.73	0.43	-0.66	0.34
Common Stock Total Equity	0.67	0.83	0.58	0.77	0.27	0.88	-0.56	-0.86	0.73	0.58	0.58		-0.28	0.48	0.94	0.72	0.88	0.77	0.29	0.83	0.66	0.24	0.83	0.13	-0.92	0.29
Common Stock Shares Outstanding	0.16	-0.4	-0.66	-0.45	0.38	-0.3	-0.17	0.41	-0.47	0.16	0.16	-0.28		0.55	-0.38	0.26	-0.42	-0.45	0.38	-0.4	0.15	0.38	-0.4	0.03	0.33	0.16
Non Current Liabilities Total	0.77	0.5	-0.2	0.19	0.66	0.4	-0.7	-0.28	0.1	0.71	0.71	0.48	0.55		0.41	0.89	0.31	0.19	0.67	0.5	0.75	0.63	0.5	0.09	-0.46	0.3
Capital Surpluse	0.62	0.87	0.7	0.86	0.18	0.88	-0.51	-0.92	0.84	0.53	0.53	0.94	-0.38	0.41		0.73	0.96	0.86	0.2	0.87	0.61	0.15	0.87	0.06	-0.94	0.24
Other Current Assets	0.74	0.68	0.23	0.58	0.43	0.61	-0.63	-0.66	0.52	0.64	0.64	0.72	0.26	0.89	0.73		0.69	0.58	0.45	0.68	0.72	0.4	0.68	-0.07	-0.73	0.23
Other Stockholder Equity	0.42	0.74	0.84	0.97	-0.07	0.74	-0.3	-0.98	0.96	0.32	0.32	0.88	-0.42	0.31	0.96	0.69		0.97	-0.05	0.74	0.41	-0.1	0.74	-0.2	-0.86	0.04
Total Liab	0.22	0.59	0.92	1.0	-0.28	0.58	-0.1	-0.97	0.99	0.12	0.12	0.77	-0.45	0.19	0.86	0.58	0.97		-0.26	0.59	0.21	-0.31	0.59	-0.39	-0.71	-0.16
Net Invested Capital	0.88	0.5	-0.52	-0.26	1.0	0.54	-0.92	0.13	-0.33	0.91	0.91	0.29	0.38	0.67	0.2	0.45	-0.05	-0.26		0.5	0.88	1.0	0.5	0.63	-0.38	0.5
Short Long Term Debt	0.79	1.0	0.39	0.59	0.48	0.88	-0.72	-0.67	0.53	0.73	0.73	0.83	-0.4	0.5	0.87	0.68	0.74	0.59	0.5		0.78	0.46	1.0	0.28	-0.91	0.34
Total Current Assets	1.0	0.78	-0.08	0.21	0.87	0.83	-0.99	-0.33	0.14	0.99	0.99	0.66	0.15	0.75	0.61	0.72	0.41	0.21	0.88	0.78		0.86	0.78	0.42	-0.73	0.38
Net Working Capital	0.86	0.46	-0.55	-0.31	1.0	0.51	-0.91	0.18	-0.38	0.9	0.9	0.24	0.38	0.63	0.15	0.4	-0.1	-0.31	1.0	0.46	0.86		0.46	0.61	-0.34	0.45
Short Term Debt	0.79	1.0	0.39	0.59	0.48	0.88	-0.72	-0.67	0.53	0.73	0.73	0.83	-0.4	0.5	0.87	0.68	0.74	0.59	0.5	1.0	0.78	0.46		0.28	-0.91	0.34
Common Stock	0.44	0.28	-0.42	-0.39	0.63	0.32	-0.44	0.26	-0.39	0.43	0.43	0.13	0.03	0.09	0.06	-0.07	-0.2	-0.39	0.63	0.28	0.42	0.61	0.28		-0.18	0.85
Current Deferred Revenue	-0.74	-0.91	-0.53	-0.71	-0.37	-0.93	0.65	0.82	-0.69	-0.66	-0.66	-0.92	0.33	-0.46	-0.94	-0.73	-0.86	-0.71	-0.38	-0.91	-0.73	-0.34	-0.91	-0.18		-0.33
Other Assets	0.42	0.34	-0.28	-0.16	0.49	0.3	-0.33	0.0	-0.15	0.34	0.34	0.29	0.16	0.3	0.24	0.23	0.04	-0.16	0.5	0.34	0.38	0.45	0.34	0.85	-0.33

Click cells to compare fundamentals

Cns Pharmaceuticals Account Relationship Matchups

Cns Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	15.9M	8.8M	13.1M	1.7M	2.0M	1.9M
Other Current Liab	519.8K	224.9K	828.4K	5.8M	6.7M	7.0M
Total Current Liabilities	1.9M	2.1M	4.9M	6.1M	7.1M	7.4M
Total Stockholder Equity	13.9M	6.6M	8.1M	(4.4M)	(5.1M)	(4.8M)
Net Tangible Assets	(549.3K)	7.6M	13.6M	6.6M	7.6M	6.0M
Net Debt	(13.6M)	(4.6M)	(9.6M)	(247.9K)	(223.1K)	(234.3K)
Retained Earnings	(20.9M)	(35.0M)	(50.7M)	(69.6M)	(62.6M)	(59.5M)
Accounts Payable	946.3K	2.0M	3.7M	5.8M	6.7M	7.0M
Cash	14.0M	5.0M	10.1M	548.7K	631.0K	599.5K
Non Current Assets Total	357.6K	1.3M	488.5K	109.7K	126.1K	119.8K
Non Currrent Assets Other	334.1K	1.3M	482.8K	104.8K	120.5K	114.4K
Cash And Short Term Investments	14.0M	5.0M	10.1M	548.7K	631.0K	599.5K
Common Stock Shares Outstanding	11.1M	17.6M	27.2M	75.3K	86.6K	82.3K
Liabilities And Stockholders Equity	15.9M	8.8M	13.1M	1.7M	2.0M	1.9M
Non Current Liabilities Total	445.8K	289.5K	1.4M	1.9M	4.1M	0.0
Other Current Assets	1.5M	2.5M	5.0M	1.0M	1.2M	1.7M
Other Stockholder Equity	34.9M	41.6M	58.8M	65.1M	74.9M	78.6M
Total Liab	1.9M	2.1M	4.9M	6.1M	7.1M	7.4M
Net Invested Capital	14.4M	7.0M	8.5M	(4.1M)	(4.8M)	(4.5M)
Total Current Assets	15.5M	7.5M	12.6M	1.6M	1.8M	1.7M
Net Working Capital	13.6M	5.3M	7.6M	(4.5M)	(5.2M)	(5.0M)
Common Stock	23.9K	27.9K	1.6K	6.2K	5.6K	5.3K
Capital Stock	23.9K	27.9K	1.6K	6.2K	5.6K	5.3K
Property Plant And Equipment Net	23.4K	16.1K	5.7K	4.9K	4.4K	4.2K

Pair Trading with Cns Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Cns Stock

0.48	GILD	Gilead Sciences Earnings Call This Week	Pair Corr
0.44	BMY	Bristol Myers Squibb Earnings Call This Week	Pair Corr

The ability to find closely correlated positions to Cns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cns Pharmaceuticals to buy it.

The correlation of Cns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Cns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Cns Stock Analysis

When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cns Historical Balance Sheet

About Cns Balance Sheet Analysis

Cns Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Cns Pharmaceuticals balance sheet Correlations

Cns Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cns Pharmaceuticals balance sheet Accounts

Pair Trading with Cns Pharmaceuticals

Moving against Cns Stock

Additional Tools for Cns Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Short Long Term Debt	+ 1.0	Short Long Term Debt Total
Short Term Debt	+ 1.0	Short Long Term Debt Total
Total Liab	+ 1.0	Total Current Liabilities
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Working Capital	+ 1.0	Total Stockholder Equity

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Total Current Assets	- 0.99	Net Debt
Other Stockholder Equity	- 0.98	Retained Earnings
Net Debt	- 0.98	Total Assets
Total Liab	- 0.97	Retained Earnings